Serum levels of interleukin-12 in patients with gastrointestinal cancer

Anticancer Research

Volumn 20, Issue 1 C, 2000, Pages 635-640

  Nakayama, Yoshifumi ^a   Shibao, Kazunori ^b   Sako, Tatsuhiko ^b   Ohta, Ryo ^b   Onitsuka, Koji ^b   Hirata, Keiji ^b   Nagata, Naoki ^b   Itoh, Hideaki ^b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b NONE

Author keywords

Colorectal cancer; Gastric cancer; Interleukin 12

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; INTERLEUKIN 12;

ADULT; ADVANCED CANCER; AGE; AGED; ANTINEOPLASTIC ACTIVITY; BLOOD LEVEL; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; PATHOLOGY; PRIORITY JOURNAL; SEROSA; STOMACH CANCER; TUMOR VOLUME;

FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INTERLEUKIN-12; MALE; MIDDLE AGED;

EID: 0034027790     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Gately MK, Wilson DE and Wong HL: Synergy between recombinant interleukin 2(rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol 136: 1274-1282, 1986.
2. Wong HL, Wilson DE, Jenson JC, Familletti PC, Stremlo DL and Gately MK: Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol 111: 39-54, 1988.
3. Stern AS, Podlaski FJ, Hulmes JD, Pan YCE, Quinn PM, Familleti PC, Stremlo DL, Truitt T, Wolitzky AG and Gately MK: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 87: 6808-6812, 1990.
4. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B and Trinchieri G: Identification and purification of natural killer cell stimulatory factor(NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170: 827-845, 1989.
5. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg H, Chizzonite R, Wolf SF and Trinchieri G: Production of natural killer cell stimulatory factor(interleukin 12) by peripheral blood mononuclear cells. J Exp Mod 176: 1387-1398, 1992.
6. Romagnani S: Induction of TH1 and TH2 responses: a key role for the 'natural' immune response?. Immunol Today 13: 379-381, 1992.
7. Germann T, Gately MK, Schoenhaut DS, Lohoff M, Mattner F, Fischer S, Jin SC, Schmitt E and Rude E: Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1(Th1) but not on Th2 cells. Hur J Immunol 23: 1762-1770, 1493.
8. Hsieh C-S, Macatonia SE, Tripp CS, Wolf SF, O'Garra A and Murphy KM: Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549, 1993.
9. Macatonia SE, Hsieh CS, Murphy KM and O'Garra A: Dendritic cells and macrophages are required for Th1 deveropment of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages stimulate IFN-gamma production is IFN-gamma-dependent. Int Immunol 5: 1119-1128, 1993.
10. Romani L, Mencacci A, Tonnetti L, Spaccapelo R. Cenci E, Wolf S, Puccetti P and Bistoni F: Interleukin-12 but not interferon-g production correlates with induction of T helper type-1 phenotype in murine candidiasis. Eur J Immunol 24: 909-915, 1994.
11. Hendrzak LA and Brunda MJ: Biology of disease. Interleukin 12: biologic activity, therapeutic utility and role in disease. Lab Investig 72: 619-637, 1945.
12. Mosmann TR and Coffman RL: Heterogenicity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 46: 111-147, 1989.
13. Del Prete G, Magy E and Romagnani S: Human Th1 and Th2 cells: functional properties, mechanism of regulation and role in disease. Lab Investig 70: 299-306, 1994.
14. Schmitt A, Hoehn P, Germann A and Rüde E: Differential effects of interleukin-12 on the development of naive mouse CD4+ T cells. Eur J Immunol 24: 343-347, 1494.
15. Stern AS, Magram J and Presky DH: IL-12: an integral cytokine in the immune response. Life Science 58: 639-654, 1496.
16. Andrew JV, Schoof DD, Bertagnolli MM, Peoples GE, Goedgebuure PS and Eberlein TJ: Immunomodulatory effects of interleukin 12 on human tumoe-infiltrating lymphcytes. J Immunother 14: 1-10, 1993.
17. Mehrotra PT, Wu D, Crim JA, Mostowski HS and Siegel JP: Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 151: 2444-2452, 1993.
18. Germann T and Rude E: Interleukine-12. Int Arch Allergy Immunol 108: 103-112,1995.
19. Trinchieri G: Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 14: 335-338, 1943.
20. Hendrzak JA, Luistro L, Gately MK, Garotta G and Brunda MJ: Role of interferin gamma in mediating the antitumor effects of interleukin-12(abstruct 3125). Proc Am Assoc Cancer Res 35: 524, 1994.
21. Brunda MJ, Luistro L, Warrior RR, Wright RB, Hubbard BR, Murphy M, Wolf SF and Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exip Med 178: 1223-1230, 1993.
22. O'Tool M, Wolf SF, O'Brien C: Effect of in vivo IL-12 administration on murine tumor cell growth. J immunol 150: 294A, 1993.
23. Tahara H, Zeh HJ, Storkus WJ III, : Fibroblasts genetically engineered to secrete IL-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54: 182-189, 1494.
24. Nastala CL, Edington HD, Mckinney TG Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ and Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153: 1697-1706, 1994.
25. Stern LL, Tarby CM, Tamborini B and Truitt GA: Preclinical development of IL-12 as an anticancer drug: comparison to IL-2(abstruct 3100). Proc Am Assoc Cancer Res 35: 520, 1994.
26. Hiscox S, Halleth MB, Puntis MCA and Jiang WG: Inhibition of cancer cell motility and invasion by IL-12. Clin Exp Metastasis 13: 396-404, 1995.
27. Mayor S, O'Donnell M and Clinton SK: Interleukine-12(IL-12) immunotherapy of experimental bladder cancer(abstract 2827). Proc Am Assoc Cancer Res 35: 474, 1994.
28. Banks RE, Patel PM and Selby PJ: Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 71: 655-659, 1995.
29. Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM and Hamilton TA: Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 156: 693-699, 1996.
30. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH and Tosato G: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182: 155-162, 1995.
31. Luster AD, Greenberg SM and Leder P: The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182: 219-231, 1995.
32. Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H and Bukowski R: Phase 1 trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4: 1183-1191, 1998.
33. Atkins MB, Robertoson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H and Sherman ML: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3: 409-417, 1997.
34. Matsuda T and Hirano T: Interleukin-6(IL-6). Biotherapy 2: 363-373, 1990.
35. Moore KW, O'Garra A, De Waal-Malefyt R, Vieira P and Mosmann TR: Interleukin-10. Ann Rev Immunol 11: 165-199, 1993.
36. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 10: 180-199, 1992.
37. Martinotti A, Stoppacciaro A, Vagliani M, Melani C, Spreafico F, Wysocka M, Parmiani G, Trinchieri G and Colombo MP: CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with IL-12 genes. Eur J Immunol 25: 137-146, 1995.
38. Brunda MJ, Luistro L, Hendrzak JA. : Role of interferon-γ in mediating the antitumor efficacy of interleukin-12, J Immunother 17: 71-77, 1995.
39. Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C and Stoppacciaro A: Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 56: 2531-2534, 1996.
40. Numata M, Minagawa T, Asano M, Nakane A, Katoh H and Tanabe T: Functional evaluation of tumor-infiltrating mononuclear cells. Detection of endogenous interferon-g and tumor necrosis factor-a in human colorectal adenocarcinomas. Cancer(Phila.) 68: 1937-1943, 1991.
41. Monson JRT, Ramsden CW and Guillou PJ: Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg 73: 483-486, 1986.
42. Wang P, Wu P, Siegel MI, Egan RW and Motasim Billah M: IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 153: 811-816, 1994.
43. O'Hara RJ, Greenman J, MacDonald AW, Gaskell KM, Topping K.P. Duthie GS, Kerin MJ, Lee PWR and Monson JRT: Advanced colorectal cancer is associated with impaired Interleukin 12 and enhanced Interleukin 10 production. Clin Cancer Res 4: 1943-1948, 1998.
44. Lissoni P, Rovelli F, Pittalis S, Casati M, Perego MS, Grassi MG, Brivio F and Fumagalli L: Interleukin-12 in early or advanced cancer patients. Eur J Cancer 33: 1703-1705, 1997.